The research team led by Prof. Peter A. Calabresi, director of the Multiple Sclerosis Center at Johns Hopkins Medical School, USA, and D&D Pharmatech developed NLY01, an autoimmune encephalomyelitis animal model. It was announced that the study result of anti-neuroinflammation response and neuroprotective function in a mouse model induced by encephalomyelitis was published in Neurotherapeutics, a renowned international academic journal in the field of brain diseases.
Multiple course is a chronic neuroimmune disease that occurs in the central nervous system, including the brain, spinal cord, and optic nerve. The research team of Neuraly, Inc., a subsidiary of D&D Pharmatech, jointly participated in the study.
In this study, the neuroinflammation and neuroprotective function of the GLP-1R agonist class has recently been attracting attention. This is a study that confirmed whether the same function can be performed in animal models.
According to the study results, when NLY01 was administered for the purpose of disease prevention, it delayed disease progression and greatly reduced disease severity. In addition, when administered for therapeutic purposes, it was shown to significantly reduce the clinical indicators of disease and relapse in relapsing-remitting multiple sclerosis. Through this, the research team predicted that NLY01 could have a dual effect in multiple sclerosis by inhibiting the inflammatory response and nerve loss of peripheral and central nerves.
Seulgi Lee, CEO of D&D Pharmatech, said, “We recently confirmed that NLY01 is also effective in glaucoma, a degenerative eye disease, and this time, we confirmed the therapeutic effect of NLY01 in multiple sclerosis. As the scientific evidence that NLY01, which can effectively inhibit the reaction, can be developed as a treatment for various neurodegenerative diseases as well as Parkinson’s disease and Alzheimer’s disease, is becoming more solid, expectations for clinical success have also grown.”